玻璃体腔内注射康柏西普治疗黄斑病变的效果观察

Effect observation of intravitreal injection of Conbercept in the treatment of macular diseases

目的 探讨玻璃体腔内注射康柏西普治疗黄斑病变的临床效果。方法 75例(102眼)黄斑病变患者,按疾病类型分为总体组(102眼, 75例)及糖尿病性黄斑水肿(DME)组(51眼, 30例)、视网膜静脉阻塞(RVO)-继发黄斑水肿(ME)组(21眼, 20例)、新生血管性年龄相关性黄斑变性(nAMD)组(17眼, 13例)、其他类型组(13眼, 12例)。所有患者均行玻璃体腔内注射康柏西普治疗。比较五组治疗前后黄斑中心凹视网膜厚度(CST)和黄斑平均厚度(CAT),并统计康柏西普注射次数。结果 总体组、DME阻、RVO-ME组、其他类型组治疗后的CST水平分别为281(247, 340)、301(257, 354)、(288±87)、247(223, 340)μm,均低于治疗前的374(301, 525)、362(303, 461)、(505±168)、508(316, 570)μm,差异具有统计学意义(P<0.05)。nAMD组治疗前后CST水平比较差异无统计学意义(P>0.05)。总体组、DME组治疗后的CAT水平分别为319(279, 351)、339(309, 364)μm,均低于治疗前的334(290, 390)、347(325, 425)μm,差异均具有统计学意义(P<0.05);RVO-ME组、nAMD组、其他类型组CAT水平比较,差异均无统计学意义(P>0.05)。总体组康柏西普注射次数<3针有54眼(53%), 3~6针有44眼(43%)、>6针有4眼(4%)。结论 玻璃体腔内注射康柏西普对黄斑病变的治疗是有效的,但是药物价格昂贵,治疗经济负担重,多数患者还是难以坚持按需治疗。

Objective To discuss the clinical effect of intravitreal injection of Conbercept in the treatment of macular diseases.Methods 75 patients(102 eyes)with macular disease were divided into overall group(102 eyes,75 cases),diabetic macular edema(DME)group(51 eyes,30 cases),retinal vein occlusion(RVO)-macular edema(ME)group(21 eyes,20 cases),neovascular age-related macular degeneration(nAMD)group(17 eyes,13 cases),other type group(13 eyes,12 cases).All patients received intravitreal injection of Conbercept.The central subfield thickness(CST)and cube average thickness(CAT)before and after treatment were compared in the five groups,and the number of Conbercept injections was counted.Results After treatment,the CST levels in the overall group,DME group,RVO-ME group and other type group were 281(247,340),301(257,354),(288±87),247(223,340)μm,which were lower than the levels of 374(301,525),362(303,461),(505±168),508(316,570)μm before treatment,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the level of CST in nAMD group before and after treatment(P>0.05).After treatment,the CAT levels in the overall group and the DME group were 319(279,351)and 339(309,364)μm,which were lower than those of 334(290,390)and 347(325,425)μm before treatment,and the differences were statistically significant(P<0.05).There was no statistically significant difference in CAT level among RVO-ME group,nAMD group and other type group(P>0.05).The overall group had 54 eyes(53%)with<3 injections of Compazepam,44 eyes(43%)with 3-6 injections,and 4 eyes(4%)with>6 injections.Conclusion Intravitreal injection of Conbercept can reduce CST and CAT in patients with macular disease and help restore visual function.However,due to the heavy economic burden,most patients cannot achieve on-demand treatment.